CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 719 enrolled
Drug / intervention
Bevacizumab-Pfizer +3 moredrug
Likely dose
Bevacizumab-Pfizer 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02364999
NCT02364999Phase 3Completed
CompareCT.gov

A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.

Pfizer·interventional·Posted Feb 18, 2015·Updated Feb 7, 2019

In Brief

A Phase 3 clinical trial evaluating Bevacizumab-Pfizer, Bevacizumab-EU, and 2 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 719 participants across 263 sites in 27 countries.

Detailed Summary

This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustralia, Brazil, Bulgaria, Chile, Croatia, Czechia, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Netherlands, Philippines, Poland, Romania, Russia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 18, 2015
Enrollment StartApr 1, 2015
Primary CompletionMay 1, 2017
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.4 years ago

Interventions

Bevacizumab-Pfizerdrug

Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.

Bevacizumab-EUdrug

bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.

Paclitaxeldrug

Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.

Carboplatindrug

carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.